ReviewTherapeutic advances in medical oncology2022

Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.

Prapassorn Thirasastr et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.